Contents

MASTERS OF IMMUNOLOGY

201  Macrophages: Gatekeepers of Tissue Integrity
      Yonit Lavin and Miriam Merad

CANCER IMMUNOLOGY AT THE CROSSROADS: COMPLEMENTARY THERAPEUTIC MODALITIES

210  Temperature Matters! And Why It Should Matter to Tumor Immunologists
      Elizabeth A. Repasky, Sharon S. Evans, and Mark W. Dewhirst

MEETING REPORT

217  Koch Institute Symposium on Cancer Immunology and Immunotherapy
      Adam Drake, Nikhil S. Joshi, Gregory L. Szeto, Eric F. Zhu, Herman N. Eisen, and Darrell J. Irvine

CANCER IMMUNOLOGY MINIATURE

223  Chronic Lymphocytic Leukemia Monitoring with a Lamprey Idiotope-Specific Antibody
      Hirotomo Nakahara, Brantley R. Herrin, Matthew N. Alder, Rosa Catera, Xiao-Jie Yan, Nicholas Chiorazzi, and Max D. Cooper

229  Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
      Derek Ng Tang, Yu Shen, Jingjing Sun, Sijin Wen, Jedd D. Wolchok, Jianda D. Yuan, and Philipp E. Thorgeirsson

235  Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
      Shigehisa Kitano, Takemasa Tsuji, Cailliam Liu, Daniel Hirschhorn-Cyerman, Chrisann Kyi, Zhenyu Mu, James P. Allison, Sacha Gnajtic, Jianda D. Yuan, and Jedd D. Wolchok

Synopsis: Using archived blood samples from 4 NY-ESO-1-seropositive patients with advanced melanoma who were treated with the CTLA-4-blocking monoclonal antibody ipilimumab, Kitano and colleagues analyzed changes in antigen-specific CD4+ T cells during cancer immunotherapy. They characterized a novel consequence of the CTLA-4 blockade, the induction or expansion of tumor-reactive cytotoxic CD4+ T cells after ipilimumab treatment.

245  Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression
      Shannon K. Oda, Pamela Strach, Yuko Fujiwara, Amin Al-Shami, Tamas Oravecz, Gabor Tigyi, Roberta Peland, and Raul M. Torres

Synopsis: Oda and colleagues show that lysophosphatidic acid (LPA) suppression of T-cell activation and proliferation is mediated by the LPA1 receptor expressed by CD8 T cells, and that LPA1-deficient CD8 T cells are more efficient in controlling the growth of established tumors in a murine melanoma model. These data suggest that LPA1 blockade may provide an additional strategy to promote tumor immunity.

256  Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation
      Yi Yin, Xianmin Huang, Kristi D. Lynn, and Philipp E. Thorpe

Synopsis: Through their treatment of mouse models of human prostate cancer with the combined regimen of docetaxel and 2aG4, the mouse IgG2a version of bavituximab, a humanized antiphosphatidylserine (anti-PS)-targeting chimeric antibody (Ab) currently being tested in clinical trials for cancer, Yin and colleagues explored potential strategies by which anti-PS-targeting Ab alter the tumor microenvironment to restore tumor immunity.
ABOUT THE COVER

Macrophages are a heterogeneous population of tissue resident hematopoietic cells. This figure illustrates key cell surface markers of mouse macrophage and monocyte populations. Macrophages can be identified by a combination of cell surface markers, including the hematopoietic lineage marker CD45, the integrin CD11b, and the GPCR F4/80, among other markers. However, macrophages in different organs have different compositions and expression levels of these cell surface proteins, reflecting their inherent diversity. CD169, sialoadhesin, is an important marker in certain macrophage populations such as the bone marrow, spleen, and lung. CX3CR1 helps to identify macrophages in the intestine and to differentiate the blood monocyte subsets. For details, see the Masters of Immunology article by Lavin and Merad on page 201 of this issue.

ABOUT THE MASTER

Miriam Merad, MD, PhD, is Professor of Oncological Science in the Department of Medicine and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York. Dr. Merad received her MD from the University of Algiers, Algeria. She did her residency in hematology and oncology in Paris, France, and obtained her PhD in immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai School of Medicine in 2004 and was promoted to the rank of associate professor with tenure in 2007 and to full professor in 2010.

In 2010, Dr. Merad became the program leader of the Cancer Immunology Immunotherapy Group at The Tisch Cancer Institute and the director of the Human Immunomonitoring Center. Dr. Merad also serves as the associate director for the MD/PhD Program at Mount Sinai Medical School.

Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of innate myeloid cells, including dendritic cells, Langerhans cells, and macrophages. The Merad laboratory has made seminal discoveries in Langerhans cells and macrophage biology revealing their embryonic origin and their local maintenance in situ. Dr. Merad’s laboratory has also extensively studied the mechanisms that control dendritic cells and macrophage homeostasis and function in barrier tissues such as the skin, lung, and gut. More recently she joined the ImmGen Consortium to help decipher the transcriptional regulation of the tissue dendritic cell and macrophage lineage. Currently, one of the major goals of the Merad laboratory is to identify the contribution of innate myeloid cells to disease outcome, including cancer and microbial immunity.

Dr. Merad has authored more than 100 primary papers and reviews in high-profile journals and obtained extensive NIH funding for her studies on dendritic cells and macrophage biology in mice and humans.

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org